Polystyrene Divinyl Benzene Beads for Enteral Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation and septic shock often involve systemic manipulation of the immune response, which can be risky and less targeted, and existing technologies fail to effectively address the localized expression of inflammatory mediators in the gut lumen, leading to tissue injury and multiple organ failure.
Innovation Solution
A composition consisting of polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer beads, designed for enteral administration, which adsorb inflammatory mediators such as cytokines from the intestinal lumen, providing a targeted approach to mitigate systemic inflammation and shock.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic manipulation of the immune response is used to treat inflammation, then the treatment can address systemic inflammatory mediators, but it carries high risk and lacks targeted precision
Solution Approach 1:
The invention divides the treatment approach into two segments: (1) enteral administration of adsorbent beads to target the gut lumen specifically, and (2) selective adsorption of inflammatory mediators at the site of highest concentration. This segmentation allows localized treatment of the gut while avoiding systemic manipulation, thereby improving safety while maintaining targeted precision.
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic action specifically in the gut lumen where inflammatory mediators are most abundant. The adsorbent beads are designed to function locally in the intestinal environment, creating a high concentration of therapeutic effect at the target site without distributing the treatment systemically, thus achieving both safety and targeted precision.
2Reliability
If hemoadsorption devices are used to remove inflammatory mediators from blood, then cytokine removal can be achieved, but the treatment is complex and requires extracorporeal circulation
Solution Approach 1:
The invention extracts the adsorption function from the complex hemoadsorption device and transfers it to simple enteral beads that can be administered orally. By taking out the essential mediator-removal function and placing it in a simple, self-contained bead form that works in the gut lumen, the treatment achieves cytokine removal efficacy without requiring complex extracorporeal circulation systems.
Solution Approach 2:
The adsorbent beads are designed to function autonomously in the gut lumen without requiring external life support systems. The beads self-service by adsorbing inflammatory mediators directly in the intestinal environment, eliminating the need for complex hospital-based hemoadsorption equipment and extracorporeal circulation infrastructure.
3Ease of manufacture
If activated charcoal is used for enteric adsorption, then some inflammatory mediators can be adsorbed, but the adsorption capacity and selectivity are insufficient
Solution Approach 1:
The patent employs composite materials by combining polystyrene divinyl benzene copolymer (providing adsorption capacity) with polyvinyl pyrrolidone coating (providing biocompatibility and selectivity). This composite structure creates beads with superior adsorption capacity and mediator selectivity compared to activated charcoal, while maintaining ease of manufacture through established polymer synthesis techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively removes inflammatory mediators from the gut lumen, reducing tissue injury and improving survival rates in septic animals by localizing the adsorption process, thereby addressing the limitations of systemic treatments.
Implementation Method 1
A composition consisting essentially of both (a) polystyrene divinyl benzene copolymer and (b) a polyvinyl pyrrolidone polymer as sorbent polymers... intraluminal adsorption of mediators of inflammation
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The invention provides a method of ameliorating systemic inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.